ISPOR and AMCP advertising available. Contact firstname.lastname@example.org.
|IN THIS ISSUE|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|Should the Cancer Drug Fund Use NICE’s Cost-Effectiveness Process?|
The NHS has announced for the first time that it will need to assess the price of the medicines passing through the Cancer Drugs Fund. This coming after the government announced it was having to add a considerable amount of money each year to the pot. Will NICE’s QALY formula for assessing the cost-effectiveness of drugs be merged with the CDF? (Source: Pharmafile, 3/9/14).
Germany’s IQWiG. It’s a No for Incontinence, Yes for Hepatitis C.
Germany’s health guidance body, IQWiG has recently published evaluations on Astellas’ Betmiga for overactive bladder, and Jenssen’s Olysio for hepatitis C. It was a positive recommendation for Janssen’s hepatitis C treatment, but Astellas’ OAB drug was not as lucky. (Source: Thomas Meek, PMLiVE, 9/2/14).
Product Pricing In Emerging Markets. Going Local?
Discussing the challenges in these emerging markets and the lack of infrastructure, the idea of a local partner is essential for success. (Source: CuttingEdge Information, 9/10/13).
Elsevier To Market New Patient Data Collection Platform.
Tonic Health’s intuitive patient data collections platform, exclusively marketed by Elsevier, enables providers to collect more accurate information from patients and use it to make better care decisions that improve outcomes and reduce costs. The solution includes a powerful, easy-to-use survey builder that allows providers to create, manage and edit all surveys, forms and questionnaires across their enterprise. (Source: PR Newswire, 9/2/14).
Bigger isn’t always better, less is sometimes more, and just because it’s new doesn’t mean it’s for you! These are some of the ideas proponents of value based insurance are hoping to spread. About 1/3 of America’s healthcare spending is attributed to wasteful or ineffective care. With this new type of insurance, if you want more, bigger and newer procedures-you’ll have to pay for them. (Source: Reuters, 12/19/13).
After gaining access to 10,000 patient records in China, Roche applied its Real World Data strategy to the records and this led them to reduce the patients process from 40 steps to just 9.
University Of York – Centre For Reviews And Dissemination.
This platform comprises health economics and outcomes research (HEOR), and market access HTA data, along with other key datasets. Reimbursement Risk Tracker (RRT) focuses specifically on the behavior of Health Technology Assessment (HTA) agencies around the world, offering an insightful look into the complex and often confusing drug development process. (Source: ContextMatters, 8/20/14).
HEOR goes high-tech, and HealthEconomics.Com is leading the way. Agenda released on the industry’s FIRST “virtual” summit on Real World Evidence (FREE! full-day virtual meeting): review, register, and reap the benefits! Register now for December 11, Real World Evidence Virtual Summit: Practical Strategies for Addressing the Needs of Multiple Stakeholders.
|Link of the Week||Conference of the Week||Webinar of the Week|